METABOLIC SYNDROME IN PATIENTS WITH GOUT AND ITS IMPACT ON THE RISK OF CARDIOVASCULAR DISEASES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The prevalence of metabolic syndrome (MS) and its individual components in patients with gout was studied. Total risk of cardiovascular disease (CVD) in this group of patients was evaluated. The study involved 86 patients, the study group comprised 56 patients with primary chronic gout and MS, the comparison group consisted of 30 volunteers with MS without gout or any other inflammatory process. All patients underwent assessment of total CVD risk according to the PROCAM and SCORE scales. At least 1 additional symptom of MS was diagnosed in aft examined patients. In 13 patients (23,21%) of the main group and 1 (3,33%) patient of the comparison group aft 5 additional signs were identified. In patients of the main group we often identified more than 3 additional signs of MS. Arterial hypertension was detected in patients with MS regardless of the presence of gout. Total risk of CVD in patients of the main group was refiabfy higher in comparison with the group with isolated MS (p<0,01 for SCORE and p<0,05 for PROCAM).

Full Text

Restricted Access

About the authors

Irina Mikhailovna Marusenko

Petrozavodsk State University; Ministry of Health of the Republic of Karelia

Email: imarusenko@yandex.ru
MD, Professor; Professor of the Department of Hospital Therapy; Chief rheumatologist 185010, Petrozavodsk, 33 Lenin av

Irina Igorevna Polskaya

Petrozavodsk State University

Email: irina_polskaya82@mail.ru
PhD, Associate Professor of the Department of Hospital Therapy 185010, Petrozavodsk, 33 Lenin av

Tatiana Ivanovna Kulagina

Petrozavodsk State University

Email: tik141@mail.ru
PhD, Associate Professor of the Department of Hospital Therapy 185010, Petrozavodsk, 33 Lenin av

Nataliya Nikolaevana Vezikova

Petrozavodsk State University

Email: vezikov23@mail.ru
MD, Professor, Head of the Department of Hospital Therapy 185010, Petrozavodsk, 33 Lenin av

References

  1. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
  2. Барскова В.Г., Елисеев М.С., Насонов Е.Л., Якунина И.А. Синдром инсулинорезистентности у больных подагрой и его влияние на формирование клинических особенностей болезни. Тер. архив. 2004;76(5):51-6.
  3. Despres J.P., Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881-7.
  4. Sidiropoulos P.I., Karvounaris S.A., Boumpas D.T. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthr. Res. Ther. 2008;10:207-6.
  5. Мамедов М.Н. Алгоритмы диагностики и лечения метаболического синдрома в клинико-амбулаторных условиях. Кардиология. 2005;45(5):92-9.
  6. Мамедов М.Н. Метаболический синдром: от разногласий к компромиссу. Болезн. серд. сосуд. 2006; 1 (4):2-6.
  7. Мамедов М.Н., Метельская В.А., Перова Н.В. Метаболический синдром: пути реализации атеротромбогенного потенциала. Кардиология. 2000;40(2):83-9.
  8. Перова Н.В., Метельская В.А., Оганов Р.Г. Метаболический синдром: патогенетические взаимосвязи и направления коррекции. Тер. арх. 2001;73(3):4-8.
  9. Ройтберг Г.Е., Ушакова Т.И., Дорош Ж.В. Роль инсулинорезистентности в диагностике метаболического синдрома. Кардиология. 2004;44(3):94-9.
  10. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., Salonen J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709-16.
  11. Чазова И.Е., Мычка В.Б. Метаболический синдром и артериальная гипертензия. Артер. гипертенз. 2002;7(1):7-10.
  12. Шостак Н.А., Аничков Д.А. К вопросу о диагностических критериях метаболического синдрома. РМЖ. 2002;10(27):55-
  13. Шостак Н.А., Аничков Д.А. Метаболический синдром: критерии диагностики и возможности антигипертензивной терапии. РМЖ. 2002;10(27):58-61.
  14. Эриванцева Т.Н., Олимпиева В.В., Чазова И.Е., Мычка В.Б. Метод установления наличия метаболического синдрома у пациентов с артериальной гипертензией и ожирением. Тер. арх. 2006;78(4):9-15.
  15. Stark K., Reinhard W., Grassl M., Erdmann J., Schunkert H., Illig T., Hengstenberg C. Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS ONE. 2009;4(11):1-7.
  16. Choi H.K., Ford E.S., Li C.Y., Curhan G. Prevalence of the Metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthr. Rheum. 2007;57(1):109-15.
  17. Yoo T.W., Sung K.C., Shin H.S., Kim B.J., Kim B.S., Kang J.H., Lee M.H., Park J.R., Kim H., Rhee E.J., Lee W.Y., Kim S.W., Ryu S.H., Keum D.G. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ. J. 2005;69:928-33.
  18. Edwards N.L. The role of hyperuricemia and gout in kidney and cardiovascular disease. Clev. Clin. J. Med. 2008;75:13-6.
  19. Nakagawa T., Mazzali M., Kang D.H., Kanellis J., Watanabe S., Sanchez-Lozada L.G., Rodriguez-Iturbe B., Herrera-Acosta J., Johnson R.J. Hyperuricemia causes glomerular hypertrophy in the rat. Am. J. Nephrol. 2003;23(1):2-7.
  20. Ouppatham S., Bancha S., Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population. J. Postgrad. Med. 2008;54(4):259-62.
  21. Pillinger M.H., Goldfarb D.S., Keenan R.T. Gout and its comorbidities. Bull. N.Y.U. Hosp. Joint Dis. 2010;68(3):199-203.
  22. Redon J., Narkiewicz K. Hypertension in the metabolic syndrome. Pol. Arch. Med. Wewn. 2009;1 19(4):255-60.
  23. Feig D.I., Kang D., Johnson R.J. Uric acid and cardiovascular risk. N. Engl. J. Med. 2008;359(17):1811-21.
  24. Schretlen D.J., Inscore A.B., Vannorsdall T.D., Kraut M., Pearlson G.D., Gordon B., Jinnah H.A. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007;69:1418-23.
  25. Wallace S.L., Robinson H., Masi A.T., Decker J.L., McCarty D.J., Yü T.F. Preliminary criteria for the classification of the acute arthritis of gout. Arthr. Rheum. 1977;20:895-900.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies